Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma

被引:4
作者
Li, Zhiru [1 ,2 ,3 ]
Li, Chao [4 ]
Yang, Dong [2 ,3 ]
Zhou, Ziyan [2 ,3 ]
Kang, Min [2 ,3 ]
机构
[1] Qionglai Med Ctr Hosp, Sichuan Prov Peoples Hosp, Dept Radiat Oncol, Chengdu, Sichuan, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Radiat Oncol, Nanning, Guangxi, Peoples R China
[3] Guangxi Tumor Radiat Therapy Clin Med Res Ctr, Nanning, Guangxi, Peoples R China
[4] Qionglai Med Ctr Hosp, Sichuan Prov Peoples Hosp, Dept Obstet & Gynecol, Chengdu, Sichuan, Peoples R China
基金
中国国家自然科学基金;
关键词
INTENSITY-MODULATED RADIOTHERAPY; STAGING SYSTEM; EDITION; EPIDEMIOLOGY; SURVEILLANCE; MULTICENTER; VALIDATION; OUTCOMES; HEAD; ERA;
D O I
10.1155/2023/7126881
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective. To establish and validate a nomogram to predict the overall survival (OS) and cancer-specific survival (CSS) in patients with nasopharyngeal carcinoma (NPC) receiving radiotherapy by integrating multiple independent prognostic factors. Materials and Methods. Data from 5663 patients with NPC who received definite radiotherapy between 2004 and 2018 were included and divided into training and validation cohorts. Univariate and multivariate Cox regression analyses were performed to determine the independent prognostic factors of patients with NPC after radiotherapy. Thereafter, the predictive accuracy of the nomogram model was evaluated. Results. Age, race, marital status, pathological type, tumor size, T stage, N stage, M stage, American Joint Committee on Cancer stage, and chemotherapy were independent factors affecting the prognosis of patients with NPC receiving radiotherapy. Nomograms with a concordance index of 0.726 (95% confidence interval (CI): 0.675-0.777) and 0.732 (95% CI: 0.680-0.785) were able to predict OS and CSS, respectively. The area under the curve showed excellent predictive performance. Additionally, the calibration curve indicated that the predicted survival rate was consistent with the actual survival rate, and the decision curve indicated its clinical value. The established risk stratification system was able to accurately stratify patients receiving radiotherapy for NPC into three risk subgroups with significant differences in prognosis (P < 0.05). Conclusions. The constructed nomogram had good prognostic performance and could be used as an effective tool to evaluate the prognosis of patients with NPC after radiotherapy. This nomogram could be further used to guide clinical decisions and personalized treatment plans.
引用
收藏
页数:18
相关论文
共 41 条
  • [11] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Dikshit, Rajesh
    Eser, Sultan
    Mathers, Colin
    Rebelo, Marise
    Parkin, Donald Maxwell
    Forman, David
    Bray, Freddie
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) : E359 - E386
  • [12] Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma
    Guo, Rui
    Tang, Ling-Long
    Mao, Yan-Ping
    Du, Xiao-Jing
    Chen, Lei
    Zhang, Zi-Chen
    Liu, Li-Zhi
    Tian, Li
    Luo, Xiao-Tong
    Xie, Yu-Bin
    Ren, Jian
    Sun, Ying
    Ma, Jun
    [J]. CANCER, 2019, 125 (01) : 79 - 89
  • [13] Multi-institutional validation of a new renal cancer-specific survival nomogram
    Karakiewicz, Pierre I.
    Briganti, Alberto
    Chun, Felix K. -H.
    Trinh, Quoc-Dien
    Perrotte, Paul
    Ficarra, Vincenzo
    Cindolo, Luca
    De la Taille, Alexandre
    Tostain, Jacques
    Mulders, Peter F. A.
    Salomon, Laurent
    Zigeuner, Richard
    Prayer-Galetti, Tommaso
    Chautard, Denis
    Valeri, Antoine
    Lechevallier, Eric
    Descotes, Jean-Luc
    Lang, Herve
    Mejean, Arnaud
    Patard, Jean-Jacques
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (11) : 1316 - 1322
  • [14] Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients
    Kim, Kelly Y.
    Quynh-Thu Le
    Yom, Sue S.
    Ng, Raymond H. W.
    Chan, K. C. Allen
    Bratman, Scott V.
    Welch, John J.
    Divi, Rao L.
    Petryshyn, Raymond A.
    Conley, Barbara A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (05): : 996 - 1001
  • [15] HOW DOES INTENSITY-MODULATED RADIOTHERAPY VERSUS CONVENTIONAL TWO-DIMENSIONAL RADIOTHERAPY INFLUENCE THE TREATMENT RESULTS IN NASOPHARYNGEAL CARCINOMA PATIENTS?
    Lai, Shu-Zhen
    Li, Wen-Fei
    Chen, Lei
    Luo, Wei
    Chen, Yuan-Yuan
    Liu, Li-Zhi
    Sun, Ying
    Lin, Ai-Hua
    Liu, Meng-Zhong
    Ma, Jun
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (03): : 661 - 668
  • [16] Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy
    Lam, Ka-On
    Lee, Anne W. M.
    Choi, Cheuk-Wai
    Sze, Henry C. K.
    Zietman, Anthony L.
    Hopkins, Kirsten I.
    Rosenblatt, Eduardo
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (05): : 1106 - 1112
  • [17] Treatment Deescalation Strategies for Nasopharyngeal Cancer A Review
    Lee, Anna
    Chow, James C. H.
    Lee, Nancy Y.
    [J]. JAMA ONCOLOGY, 2021, 7 (03) : 445 - 453
  • [18] Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
    Lee, Anne W. M.
    Ma, Brigette B. Y.
    Ng, Wai Tong
    Chan, Anthony T. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29) : 3356 - +
  • [19] Nasopharyngeal carcinoma: Salvage of local recurrence
    Lee, Anne W. M.
    Fee, Willard E., Jr.
    Ng, W. T.
    Chan, L. K.
    [J]. ORAL ONCOLOGY, 2012, 48 (09) : 768 - 774
  • [20] Development and Validation of a Prognostic Nomogram Based on Residual Tumor in Patients With Nondisseminated Nasopharyngeal Carcinoma
    Liao, Ping-Yan
    Dong, Zhong-Yi
    Huang, Chan-Tao
    Tang, Xin-Ran
    Liu, Guan-Dong
    Zhu-Liu
    Wu, De-Hua
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19